News

AddToAny

Google+ Facebook Twitter Twitter

IBMS responds to Dame Sally's report

The IBMS has issued a response to Professor Dame Sally Davies’ annual report, which calls on the government to develop genomic medicine’s role in the NHS.

Sarah May, IBMS Deputy Chief Executive, commented on Dame Sally’s focus on genomic testing.

“We support the Chief Medical Officer’s view that DNA testing should become standard across cancer care,” she said. 

“The UK has a workforce of highly skilled and trained biomedical scientists that are preparing to meet this new diagnostic and treatment challenge.” 

She added that the IBMS is launching two new molecular pathology qualifications in 2017. 

These are “intended to directly support the new and expanding science and technology and help to achieve Dame Sally’s vision for personalised diagnosis and healthcare”.

Related Articles

CRISPR-Cas9 gene editing complex, illustration.Image credit - Science-Photo-Library-f0248864

Activating genes using CRISPR technology

There are over 7000 different rare genetic diseases, and often it can be a significant challenge and take a long time to receive a correct diagnosis.

Blue helix human DNA structure-Image credit-shutterstock-1669326868

The search for genes that cause diseases

A new statistical tool developed by researchers at the University of Chicago improves the ability to find genetic variants that cause disease.

pathogenspreadhr-CREDIT-spooky-pooka

Figuring out the threats: Problem-solving with genomics

As the COVID-19 enquiry continues to unpick the tangled threads of the pandemic response, little has been said about one of the most effective weapons against the SARS-Cov-2 virus – pathogen genomics.

breast cancer cells - CREDIT - Science Photo Library-c0559159

Breast cancer cells’ self-sacrifice is potential cause of relapse

For patients with early-stage breast cancer, there is a 7% to 11% chance of relapse within five years after receiving initial treatment.

Top